本瑞利珠单抗治疗重度嗜酸性粒细胞性哮喘(附10例报告)OA

Objective To observe the clinical efficacy and safety of benralizumab in the treatment of severe eosino-philic asthma(SEA).Methods Ten SEA patients were enrolled and treated with benralizumab combined with back-ground medication for 4 courses.The forced expiratory volume in one second(FEV1),blood eosinophil count(BEC),asthma control questionnaire-5(ACQ-5)score,fractional exhaled nitric oxide at 50 mL/s(FeNO50),the incidence of asth-ma exacerbations and adverse drug reactions were observed and compared before benralizumab treatment(V1)and at week 16 of benralizumab treatment(V5).Results At V1,the FEV1,BEC,ACQ-5 score and FeNO50 of the 10 SEA patients were 1.70(1.27,2.23)L,0.8(0.62,1.32)×10⁹/L,1.35(0.80,2.45)points and 31.00(26.00,58.25)μg/L,respectively;at V5,the corresponding indexes were 1.89(1.45,2.86)L,0,0.50(0.15,1.20)points and 35.00(18.25,58.50)μg/L,respectively.Compared with V1,the FEV1 at V5 was significantly higher(P<0.05),while the BEC and ACQ-5 score were significantly lower(both P<0.05).Among the 10 patients,1 case experienced an asthma ex-acerbation during treatment,which was associated with influenza A infection,and the symptoms resolved after symptomat-ic treatment.Four patients developed chills and fever on the night of the first medication administration,and the symptoms resolved spontaneously after 2-4 hours without severe allergic reactions,headache,aggravated nasopharyngitis or other ad-verse events.Conclusions Benralizumab combined with background medication achieves favorable efficacy in the treat-ment of SEA.It can effectively reduce BEC,improve lung function and stably control asthma symptoms,with mild adverse reactions in patients.